Immune-based identification of cancer patients at high risk of progression.

Immune-based identification of cancer patients at high risk of progression. Curr Opin Immunol. 2018 Mar 16;51:97-102 Authors: Vano YA, Petitprez F, Giraldo NA, Fridman WH, Sautès-Fridman C Abstract Tumors are highly heterogeneous structures where malignant cells interact with a large variety of cell populations, including a clinically-relevant immune component. We review and compare the most recent methods designed to analyze and quantify the composition of immune and stromal microenvironment of tumors and discuss their use in identification of patients for high risk of progression. If the impact of the various immune components on patient's relapse share common rules in most malignancies, clear cell renal cell tumors behave differently with regards to immunity. We focus on this specific pathology to show how the tumor interacts with the host's immune system and how this intricate relationship shapes the clinical outcome. PMID: 29554496 [PubMed - as supplied by publisher]
Source: Current Opinion in Immunology - Category: Allergy & Immunology Authors: Tags: Curr Opin Immunol Source Type: research